Hydrogen Capsules Help Immune System in Lupus Heart Disease Patient

Authors
Journal
In Vivo
Year
DOI
10.21873/invivo.14165
Study Type
Human
Outcome
Positive
Peer Reviewed
Yes
Country
Taiwan
Health Condition
Systemic Lupus Erythematosus
Body System
Cardiovascular

TL;DR

In an SLE patient with pulmonary hypertension, hydrogen capsule therapy led to clinical improvement and revealed a biphasic immune response—initial suppression of T cell and B cell activation, followed by regulatory rebound after therapy cessation.

Key Finding

In one SLE patient with pulmonary arterial hypertension, hydrogen capsule therapy appeared to suppress certain immune activation markers during treatment, followed by a rebound of regulatory immune cells after therapy stopped.

Summary

This case report describes one 45-year-old woman with systemic lupus erythematosus (SLE, an autoimmune disease) who also had pulmonary arterial hypertension (PAH, high blood pressure in the lungs). She received hydrogen capsules as an additional treatment, and researchers tracked changes in her immune cells over time. They found that certain immune cells decreased while she was taking hydrogen, then increased again after she stopped—suggesting hydrogen may have a two-phase effect on the immune system.

Practical Takeaway

This is a single case report, not a controlled study, so it provides only preliminary evidence that hydrogen capsules may affect immune function in SLE-related lung disease. Much larger and more rigorous studies would be needed to determine whether hydrogen actually helps patients with this condition or what the optimal dosing and duration should be. Anyone with SLE or PAH considering hydrogen therapy should discuss it with their doctor first.

Abstract

Background/aim: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), marked by vascular remodeling, immune dysregulation, and progressive right heart failure. Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has the capacity to modulate immune responses in these autoimmune disease patients. This case report details the clinical improvement in an SLE patient with PAH after starting adjunctive hydrogen capsule therapy, highlighting its potential as a novel approach for this challenging complication. Case report: A 45-year-old Taiwanese woman with SLE-PAH who received hydrogen capsule therapy, during which serial immunophenotyping revealed dynamic changes in T cell exhaustion markers, regulatory T cell (Treg) subsets, and regulatory B cells (Breg). Notably, KLRG1+ T cells and CD39+Helios- Tregs were suppressed during therapy but rebounded after cessation, suggesting transient immune suppressing followed by regulatory rebalancing. Bregs also showed a similar pattern, declining during therapy and recovering after discontinuation. Conclusion: These findings suggest a biphasic immunomodulatory effect of hydrogen therapy, that is, initially dampening immune activation, followed by a regulatory rebound after hydrogen therapy.